Actos Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Actos Litigation

Share Article

The firm is currently investigating Actos bladder cancer lawsuits on behalf of individuals treated with the type 2 diabetes drug.

Bernstein Liebhard LLP | Consumer Injury Lawyers
We continue to hear from Actos users who were diagnosed with bladder cancer following long-term treatment with the medication. We look forward to more progress in this litigation.

Actos lawsuits continue to move forward in the federal multidistrict litigation underway in U.S. District Court, Western District of Louisiana, Bernstein Liebhard LLP reports. According to court documents, the next status conference in the federal Actos litigation has been scheduled for February 21, 2013. Scores of Actos bladder cancer lawsuits have been filed in the Western District of Louisiana that claim patients using the drug are at an increased risk for the disease. (In re: Actos Product Liability Litigation, MDL No. 2299 [W.D. La.])

“We continue to hear from Actos users who were diagnosed with bladder cancer following long-term treatment with the medication. We look forward to more progress in this litigation,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos bladder cancer lawsuit evaluations to individuals who may have been harmed by Actos.

Actos Bladder Cancer Lawsuits
The U.S. Food & Drug Administration (FDA) ordered Takeda Pharmaceuticals to add new warnings to the Actos label in June 2011, after a study found that long-term use of the drug increased the risk for bladder cancer.* A number of studies have since confirmed a connection between Actos and bladder cancer, including research published last May in the British Medical Journal which concluded that taking the drug for two years can double the risk of developing bladder cancer. ** A second study published in the Canadian Medical Association Journal in July 2012 found that patients taking Actos face a 22 percent increased risk of developing bladder cancer.***

At the time the FDA alert was issued, Actos was the best-selling diabetes drug in the world. However, Takeda recently reported that sales of the drug had fallen more than 53% in the third quarter of 2012, compared to the same period last year.**** According to, some experts have speculated that Takeda could eventually face as many as 10,000 Actos bladder cancer lawsuits.***** According to court documents, the first trial in the federal Actos litigation is scheduled to begin in November 2014, followed by the second trial in July 2015.

Actos users who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website, For additional information, contact a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.



About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website